The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 20, 2022
Filed:
Mar. 13, 2019
Applicant:
Jubilant Prodel Llc, Yardley, PA (US);
Inventors:
Chandregowda Venkateshappa, Bangalore, IN;
Jeyaraj D A, Bangalore, IN;
Muralidhar Pendyala, Bangalore, IN;
Dhanalakshmi Sivanandhan, Bangalore, IN;
Sridharan Rajagopal, Bangalore, IN;
Assignee:
Other;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4545 (2006.01); A61K 31/165 (2006.01); A61K 31/397 (2006.01); A61K 31/40 (2006.01); A61K 31/445 (2006.01); A61K 31/454 (2006.01); A61K 45/06 (2006.01); C07C 233/36 (2006.01); C07C 255/59 (2006.01); C07D 207/16 (2006.01); C07D 211/56 (2006.01); C07D 211/60 (2006.01); C07D 213/30 (2006.01); C07D 295/096 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 471/04 (2006.01); C07D 491/107 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4545 (2013.01); A61K 31/165 (2013.01); A61K 31/397 (2013.01); A61K 31/40 (2013.01); A61K 31/445 (2013.01); A61K 31/454 (2013.01); A61K 45/06 (2013.01); C07C 233/36 (2013.01); C07C 255/59 (2013.01); C07D 207/16 (2013.01); C07D 211/56 (2013.01); C07D 211/60 (2013.01); C07D 213/30 (2013.01); C07D 295/096 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 471/04 (2013.01); C07D 491/107 (2013.01);
Abstract
The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are bicyclic compounds that are inhibitors of PD-1/PD-L1 interaction/activation.